Brazil's health agency Anvisa revoked measures prohibiting the sale and advertising of medicines on large digital platforms on Monday [1].
This decision opens the pharmaceutical market to major delivery apps, potentially altering how millions of Brazilians access medication. By removing these restrictions, the agency allows platforms like iFood, Mercado Livre, and Rappi to facilitate the delivery of medicines across the country [1].
Prior to this ruling, the Agência Nacional de Vigilância Sanitária had maintained strict prohibitions against the commercialization and advertising of medicines by these digital giants [1]. The agency's shift now permits the nationwide operation of these services, integrating pharmaceutical logistics into the existing digital infrastructure of the country's largest delivery ecosystems [1].
The move comes amid a complex regulatory environment. Earlier this year, pharmaceutical associations had raised concerns regarding the storage of medications, including reports of medicines being kept in "dark stores" [2]. Those complaints specifically targeted the operational methods of delivery platforms to ensure safety and quality standards were met during transit and storage [2].
Despite those previous disputes, the current ruling clears the path for a wider rollout of digital pharmacy services. The platforms can now legally advertise their ability to deliver medications, a practice that was previously restricted under the agency's guidelines [1].
Anvisa has not provided a detailed public justification for the sudden reversal of these measures. However, the decision effectively ends the legal barrier that prevented digital platforms from competing directly in the pharmaceutical delivery space [1].
“Anvisa revoked measures prohibiting the sale and advertising of medicines on large digital platforms.”
The decision signals a shift toward the digitalization of healthcare logistics in Brazil. By allowing tech giants to enter the pharmaceutical space, Anvisa is prioritizing consumer accessibility and market efficiency. However, the move may increase friction between traditional pharmacy associations and digital platforms over safety standards and the regulation of non-traditional storage facilities.
